The FDA announced it has accepted a priority review of dupilumab for the treatment of moderate-to-severe AD in pediatric patients 6 to 11 years of age. The drug is already approved for treatment of AD in adolescents and adults.
LEO Pharma has recently announced that all three phase 3 studies examining the safety and efficacy of the atopic dermatitis investigational drug tralokinumab met all of its primary and secondary endpoints, leading way to the company now seeking marketing authorization for the drug.
The U.S. FDA has granted Dermira with a Fast Track designation for its atopic dermatitis drug lebrikizumab following the start of phase 3 clinical trials to examine the efficacy, tolerability and safety of the drug.
The United States Food and Drug Administration has granted Galderma’s nemolizumab a Breakthrough Therapy Designation following phase 2 results which suggests the drug is a considerable alleviant for pruritus associated with prurigo nodularis.
Significant variation exists in prescribing patterns among doctors managing atopic dermatitis, and the prescription of some drugs may go against dermatology guidelines, finds a recent study.
For patients with atopic dermatitis, access to dermatology care appears to be best in the West and poorest in the Midwest, shows a recent study looking at disparities in access to services across the United States.
Patients with moderate-to-severe atopic dermatitis may have a 20% increased risk of atrial fibrillation, finds a recent study.
Pain is a distinct and important symptom of atopic dermatitis experienced by almost two thirds of patients, reports a recent study.
Researchers recently analyzed insurance claims data to investigate the safety and efficacy of off-label immunomodulatory drugs for atopic dermatitis in real life practice. Read what they discovered here.
Atopic dermatitis presents differently depending on whether the patient is an adult or child. This means that different treatments may be more effective in an adult than children and vice versa.